International Association for the Study of Lung Cancer Releases new Atlas on EGFR Testing

The Atlas will provide useful guidance to better inform medical professionals on EGFR treatment

Yokohama, Japan – October 17, 2017 – The International Association for the Study of Lung Cancer (IASLC) today released its Atlas of EGFR Testing in Lung Cancer at the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. The EGFR Atlas provides health care professionals with information on EGFR testing processes and facilitates clinicians’ understanding of how to interpret the results. The Atlas also includes a summary of relevant clinical data that supports the use of EGFR testing in patients with special cases. The guidebook is the first version of the EGFR Testing Atlas but the third in an atlas series, which also includes the ALK/ROS1 and PD-L1 Testing Atlas.

Epidermal growth factor receptor (EGFR) testing is primarily used to help guide treatment and to determine whether someone with non-small cell lung cancer (NSCLC) may benefit from targeted therapy. The testing detects the presence of specific activating mutations in the EGFR gene in the DNA of tumor cells, which can lead to uncontrolled growth of cancer cells.

The guidebook provides oncological pathologists, clinicians and other health care professionals with comprehensive information on a variety of EGFR testing topics, from tumor sample best practices to reporting and quality assurance. By sharing this important educational material globally, the Atlas is intended to improve the quality of lung cancer patient care across the globe, therefore improving and prolonging the lives of patients.

“Because the use of EGFR testing is growing rapidly, this Atlas is a critical tool to ensure best practices worldwide,” said David Carbone, Fred Hirsch and Tony Mok, editors of the guide. “The IASLC is committed to developing and implementing global standards that make it possible for all lung cancer patients, regardless of where they live, to receive the best possible care. This guide empowers health care professionals to utilize EGFR testing to create better outcomes for their patients.”

The Atlas was first made available in English to attendees at the World Conference, but is also now available in PDF form on the IASLC website here in English, Japanese and Chinese. The Atlas will soon be available in Portuguese, Spanish and Korean and available in print on the IASLC website and on the conference mobile app.
About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of “Synergy to Conquer Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2017.iaslc.org.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

# # #